WTA
NTLA icon

Washington Trust Advisors’s Intellia Therapeutics NTLA Stock Holding History

Washington Trust Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29
Closed -$2K – 920
2022
Q2 		$2K Hold
29
– – ﹤0.01% 890
2022
Q1 		$2K Hold
29
– – ﹤0.01% 957
2021
Q4 		$3K Buy
+29
New +$3.63K ﹤0.01% 932

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Washington Trust Advisors's NTLA Position: Q3 2022 in Review

Washington Trust Advisors sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 29 shares — an estimated $2K sold.

Washington Trust Advisors first reported a position in NTLA in Q4 2021 and held it in 3 quarters. The position peaked at $3K in Q4 2021. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

  • Washington Trust Advisors reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Washington Trust Advisors sold 29 Intellia Therapeutics shares in Q3 2022, an estimated $2K.
  • Washington Trust Advisors first reported a position in Intellia Therapeutics in Q4 2021 and held it in 3 quarters.
  • Washington Trust Advisors's Intellia Therapeutics position peaked at $3K in Q4 2021.
  • 319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Washington Trust Advisors's 13F filing for Q3 2022, filed 14 Oct 2022.